Blood
Articles in this Issue
Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)
Abstract Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the prognosis of rel...
Outcomes with luspatercept in patients with β-thalassemia: A systematic review and meta-analysis
Abstract Background β-thalassaemia is a genetic blood disorder marked by ineffective erythropoiesis and chronic anaemia, often requiring lif...
End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Abstract Background: The Pediatric ITP Newly diagnosed patients Eltrombopag vs Standard therapy (PINES) trial, NCT03939637, was an investiga...
SRSF2 mutation induces BH3 mimetics sensitivity via BCL2L2 mis-splicing
Abstract Recent advances in next-generation sequencing have unveiled the complex mutational landscape of acute myeloid leukemia (AML), leadi...
GLP-1 agonist use is associated with reduced risk of multiple myeloma in type II diabetes.
Abstract Introduction: Glucagon-like peptide-1 (GLP-1) agonists are a staple in the treatment of type 2 diabetes mellitus and obesity. Since...
Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial
Abstract Background: Polycythemia vera (PV) is characterized by excessive erythrocytosis and elevated hematocrit (Hct), which is associated...
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) has shown high efficacy in relapsed MM, but further efforts are needed to mitig...
Reviewing management of venous thromboembolism in elderly lymphoma patients
Abstract Background: Older patients with lymphoma have an increased risk of venous thromboembolism (VTE), due to age-rel...
Artificial intelligence in oncology: A cross-sectional analysis of chatgpt and openevidence performance on ALL guidelines
Abstract Background Artificial intelligence (AI) is becoming increasingly popular amongst medical professionals. With th...
Efficacy and safety of azacitidine plus low-dose dasatinib maintenance therapy for patients with intermediate and high-risk acute myeloid leukemia: A prospective, randomized, phase Ⅱ clinical trial
Abstract Background Although some acute myeloid leukemia (AML) patients achieve minimal residual disease (MRD) negativity following inductio...
First-in-class dual BTK-MALT1 fusion inhibitors for treating resistant Mantle Cell Lymphoma
Abstract Background Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with poor prognosis in relapsed or refractory (R/R) cases,...
Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group
Abstract Introduction: Severerenal impairment (RI) is a common complication of multiple myeloma (MM), limiting therapeutic options and negati...
Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients
Abstract Background: Venetoclax is the only approved BCL2 inhibitor for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CL...
Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies
Abstract BACKGROUND Despite active therapies such as hypomethylating agents (HMA) and venetoclax advanced myeloid malignancies, outcomes in r...
Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial
Abstract Background: BCMA-targeted CAR T cells have unprecedented activity in relapsed/refractory multiple myeloma (RRMM), but the majority...
Non-coding variants in UBA1 lead to vexas
Abstract Introduction: Somatic mutations in UBA1, encoding an E1 ubiquitin activating enzyme, have recently been linked...
Real-world survey of triplet versus quadruplet regimen preferences in transplant-ineligible (TIE) or deferred patients with newly diagnosed (ND) multiple myeloma (MM)
Abstract Introduction: Historically, triplet therapy with an anti-CD38 monoclonal antibody (mAb) has been the standard (i.e., daratumumab +...
Comparative efficacy and prognostic analysis of non-intensive chemotherapy in symptomatic versus asymptomatic newly diagnosed Acute Myeloid Leukemia
Abstract Background: Acute myeloid leukemia (AML) is a malignant hematologic tumor originating from hematopoietic stem/progenitor cells in t...
Effect of race and socio-economic status in allogeneic STEM cell transplantation. a single center experience.
Abstract Background Access to and outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) have been previously associated wi...
Combinatorial targeting of metabolic vulnerabilities in t-cell leukemia through NAMPT inhibition
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that arises from the malignant transformation o...
Germline SEPT6 mutations in congenital neutropenia and myelodysplastic syndrome induce de novo protein function disrupting hematopoietic stem cell maintenance
Abstract Septin family proteins belong to the RAS-like GTPase superclass and are considered a structural element of the cytoskeleton. Septin...
The prolong trial: A two Phase randomized placebo-controlled trial to optimize rituximab response with dexamethasone and maintenance therapy with low dose rituximab in immune thrombocytopenia (ITP) patients
Abstract Background ITP is an autoimmune bleeding disorder characterized by thrombocytopenia and increased bleeding risk. Corticosteroids (C...
Understanding unmet needs for people with haemophilia a receiving factor and non-factor treatments
Abstract BACKGROUND: There is limited published real-world evidence on treatment patterns among people with severe haemophilia A (PwSHA), pa...
Integration of Cut&Run, atac-seq and RNA-seq analyses defines the impact of germline ETV6 mutations on chromatin binding and gene expression in megakaryocytes
Abstract Germline mutations in ETV6 cause thrombocytopenia and predisposition to malignancies. ETV6 (ETS Variant 6) is a transcriptional rep...
Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma
Abstract Background Translocation of chromosomes 4 and 14 (t(4;14)) results in overexpression of MMSET and has been associated with poor cli...